Combined pergolide-associated valvular heart disease (PAVHD) and Achilles tendon contractures
Abstract
A Letter to EditorDownloads
References
Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826-9.
Hu MT, Bland J, Clough C, Ellis CM, Chaudhuri KR. Limb contractures in levodopa-responsive parkinsonism: a clinical and investigational study of seven new cases. J Neurol. 1999;246(8):671-6.
Charcot JM. Lectures on the diseases of the nervous system (paralysis agitans), lecture V. London: New Sydenham Society; 1877. p. 140-7.
Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in
cardiac valvular fibrosis. Clin Neuropharmacol. 2006;29(2):80-6.
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39-46.
Fukae J, Tanaka S, Hattori N. Retroperitoneal fibrosis secondary to pergolide therapy. Intern Med. 2010;49(15):1687.
